TickerFacts.

Allogene Therapeutics, Inc. (ALLO): Shareholders' Equity

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2020-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$292.54M
As of 2025-12-31
$436.18M
As of 2026-06-30
-24.0%
3-year compound annual growth
-22.0%
5-year compound annual growth
$1.01B2017-12-31: -$2.0K2018-12-31: $703.16M2019-12-31: $629.02M2020-12-31: $1.01B2021-12-31: $925.20M2022-03-31: $865.27M2022-06-30: $806.48M2022-09-30: $743.40M2022-12-31: $666.88M2023-03-31: $592.01M2023-06-30: $621.41M2023-09-30: $580.63M2023-12-31: $512.23M2024-12-31: $422.18M2025-12-31: $292.54M$292.54M
2017-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$292.54M-30.7%2026-03-12, Balance as of period end
2024-12-31$422.18M-17.6%2026-03-12, Balance as of period end
2023-12-31$512.23Mn/a2025-03-13, Balance as of period end
2023-09-30$580.63Mn/a2024-03-14, Balance as of period end
2023-06-30$621.41Mn/a2024-03-14, Balance as of period end
2023-03-31$592.01Mn/a2024-03-14, Balance as of period end
2022-12-31$666.88Mn/a2024-03-14, Balance as of period end
2022-09-30$743.40Mn/a2024-03-14, Balance as of period end
2022-06-30$806.48Mn/a2024-03-14, Balance as of period end
2022-03-31$865.27Mn/a2024-03-14, Balance as of period end
2021-12-31$925.20M-8.7%2024-03-14, Balance as of period end
2020-12-31$1.01Bn/c2024-03-14, Balance as of period end
2019-12-31$629.02M-10.5%2022-02-23, Balance as of period end
2018-12-31$703.16Mn/m2021-02-25, Balance as of period end
2017-12-31-$2.0Kn/a2020-02-27, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Allogene Therapeutics, Inc. (ALLO)2025-12-31$292.54M-30.7%
Vaxart, Inc. (VXRT)2025-12-31$87.80M+49.0%
Amgen Inc (AMGN)2025-12-31$8.66B+47.3%
Repligen Corp (RGEN)2025-12-31$2.11B+6.8%
Champions Oncology, Inc. (CSBR)2026-04-30$3.94M+4.4%
Bio-Techne Corp (TECH)2026-06-30$2.11B+9.9%
Biogen Inc. (BIIB)2025-12-31$18.26B+9.2%
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31$43.35M-43.7%
Gilead Sciences, Inc. (GILD)2025-12-31$22.62B+17.5%

Compare ALLO, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗